Cost-effectiveness analysis of treatment modalities for women with high-intermediate risk endometrial carcinoma: Should Gynecologic Oncology Group (GOG) 249 have included a chemotherapy-only arm?

E.E Landers,R.C Arend,J.M Straughn,C.A Leath

doi:10.1016/j.ygyno.2014.03.372

Cost-effectiveness analysis of treatment modalities for women with high-intermediate risk endometrial carcinoma: Should Gynecologic Oncology Group (GOG) 249 have included a chemotherapy-only arm?

E.E Landers, R.C Arend + Show 2 more

https://doi.org/10.1016/j.ygyno.2014.03.372

Copy DOI

Journal: Gynecologic Oncology

Publication Date: Jun 1, 2014

Affiliation: University of Alabama

#Paclitaxel And Carboplatin #Whole Pelvic Radiation Therapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Objectives: GOG 249 was developed to determine if the combination of vaginal brachytherapy (BT) and three cycles of paclitaxel and carboplatin (PC) are superior to whole pelvic radiation therapy (WPRT) in terms of disease-free survival for high-intermediate risk (H-IR) endometrial cancer (EMCA) patients. Accordingly, we estimated the costs and outcomes of four treatment modalities used for the management of H-IR EMCA.

Full Text